Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

202426 citationsJournal Articlegold Open Access

Authors

The DRUG Access Protocol is supported by all participating pharmaceutical companies: Bayer, Janssen, Lilly, Merck, Novartis, Roche, and Sanofi.

Good health and well-being

Published in: The Lancet Regional Health - Europe

Volume 39, pp. 100875-100875

Field-Weighted Citation Impact: 9.96